| Old Articles: <Older 7931-7940 Newer> |
|---|
 |
Chemistry World
October 11, 2011
Andrew Turley |
A Polymer Plug for Blood Vessels A polymer product that can temporarily block blood vessels during surgery has been approved in the US. The product, called LeGoo, is liquid at room temperature, but rapidly forms a gel when warmed by the body, creating a firm plug and halting blood flow.   |
The Motley Fool
October 11, 2011
Rich Smith |
Buy This Cancer-Killer AngioDynamics is cheaper than it looks, with a significant opportunity for investors.. |
The Motley Fool
October 11, 2011
Cliff D'Arcy |
AstraZeneca Loves This $100Bn Market The British pharma firm makes its largest-ever manufacturing investment -- in China. |
The Motley Fool
October 11, 2011
Arlene Weintraub |
Agios and Celgene: Anatomy of an Ultra-Valuable Biotech Marriage An unprecedented cancer drug development deal. |
The Motley Fool
October 10, 2011
Frank Vinluan |
TRGT Tries Again With Alzheimer's Disease Drug Candidate A Targacept compound that has been studied in a range of cognitive disorders with drug partner AstraZeneca has started in mid-stage clinical studies as a potential new Alzheimer's disease treatment. |
The Motley Fool
October 7, 2011
Brian Orelli |
A Little Help, Please Gilead pumps up the pipeline. |
The Motley Fool
October 6, 2011
Brian Orelli |
Data Published; Back to Waiting Phase 2 data for Aeterna Zentaris and Keryx's perifosine was published, but it's the phase 3 that's important. |
The Motley Fool
October 6, 2011
Dan Caplinger |
Has Medco Health Solutions Become the Perfect Stock? A lot has happened in the pharmacy benefits management space since we looked at Medco last year. |
The Motley Fool
October 6, 2011
Frank Vinluan |
Duke University and Verizon Partner on New Health IT Initiative Duke University is partnering with Verizon in a health IT initiative pursuing technologies intended to improve care, expand health care access and lower costs. |
The Motley Fool
October 5, 2011
Brian Orelli |
1 Sure Sign of an FDA Approval Transcept Pharmaceuticals shoots up 34% after announcing that the FDA had classified its resubmission as a class 1 response. |
| <Older 7931-7940 Newer> Return to current articles. |
